HEC88473

Last updated June 26, 2025

HEC88473 is an experimental dual GLP-1 and fibroblast growth factor 21 (FGF21) receptor agonist. It is developed by the Chinese company HEC Pharm for diabetes and non-alcoholic steatohepatitis.^[1]^[2]

References

↑ Pan, Qi; Lin, Shushan; Li, Yu; Liu, Liang; Li, Xiaoping; Gao, Xianglei; Yan, Jiangyu; Gu, Baohua; Chen, Xiaofeng; Li, Wenjia; Tang, Xinfa; Chen, Chao; Guo, Lixin (January 2021). "A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis". eBioMedicine. 63: 103202. doi: 10.1016/j.ebiom.2020.103202 . ISSN 2352-3964. PMC 7806870 . PMID 33421947.
↑ Negi, Chander K.; Babica, Pavel; Bajard, Lola; Bienertova-Vasku, Julie; Tarantino, Giovanni (January 2022). "Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease". Metabolism. 126: 154925. doi: 10.1016/j.metabol.2021.154925 . PMID 34740573.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Pan, Qi; Lin, Shushan; Li, Yu; Liu, Liang; Li, Xiaoping; Gao, Xianglei; Yan, Jiangyu; Gu, Baohua; Chen, Xiaofeng; Li, Wenjia; Tang, Xinfa; Chen, Chao; Guo, Lixin (January 2021). "A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis". eBioMedicine. 63: 103202. doi: 10.1016/j.ebiom.2020.103202 . ISSN 2352-3964. PMC 7806870 . PMID 33421947.

[2] Negi, Chander K.; Babica, Pavel; Bajard, Lola; Bienertova-Vasku, Julie; Tarantino, Giovanni (January 2022). "Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease". Metabolism. 126: 154925. doi: 10.1016/j.metabol.2021.154925 . PMID 34740573.

[1]

[2]